Ascendis BioMarin YUVIWEL Settlement License
Analysis based on 6 articles · First reported Aug 31, 2026 · Last updated Aug 31, 2026
The settlement removes litigation overhang and secures Ascendis' ability to commercialize YUVIWEL globally, likely boosting investor confidence and supporting Ascendis' revenue growth targets. BioMarin gains a steady royalty stream without further legal costs, positively impacting its financial outlook.
Ascendis Pharma A/S and BioMarin Pharmaceutical Inc. have entered into a binding term sheet for a global settlement and license agreement resolving all litigation and disputes related to YUVIWEL (navepegritide). Under the terms, BioMarin grants Ascendis a non-exclusive, worldwide, royalty-bearing license to continue researching, developing, manufacturing, and commercializing navepegritide-related products without restriction. BioMarin also waives certain regulatory rights and exclusivities, dismisses all proceedings, and provides a covenant not to sue. In exchange, Ascendis dismisses all proceedings against BioMarin and agrees to pay royalties of 20% in the United States and 18% in the European Union, South Korea, and Brazil on net sales of navepegritide-related products from first commercial sale through May 20, 2030. The settlement removes legal uncertainty and allows Ascendis to focus on the commercial success of YUVIWEL, which was approved by the FDA in February 2026 for achondroplasia. Ascendis expects to generate over €500 million in operating cash flow in 2026 and believes it can achieve €5 billion in revenue by 2030.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard